

Company Number: 671782

Premier Morts Medical Limited
Abridged Unaudited Financial Statements
for the financial period ended 31 December 2025

Premier Morts Medical Limited

CONTENTS

	Page
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5
Notes to the Financial Statements	6 - 10

Premier Morts Medical Limited
DIRECTORS AND OTHER INFORMATION

Directors	Seyed Mohammad Mortazavi Leila Afsar
Company Secretary	Leila Afsar
Company Number	671782
Registered Office	36 The Sycamore Parkview Stepaside Dublin 18
Business Address	Long Mile Pharmacy 1 Long Mile Road Dublin 12
Accountants	RDA Accountants Limited Certified Public Accountants Unit 7C Ardcavan Business Park Ardcavan Wexford

Premier Morts Medical Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial period ended 31 December 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial period. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial period end date and of the profit or loss of the company for the financial period and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to RDA Accountants Limited, (Certified Public Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial period ended 31 December 2025."

Signed on behalf of the board

Seyed Mohammad Mortazavi
Director

19 February 2026

Leila Afsar
Director

19 February 2026

Premier Morts Medical Limited

BALANCE SHEET

as at 31 December 2025

	Notes	Dec 25 €	Jul 25 €
Fixed Assets			
Tangible assets	7	<u>443,802</u>	<u>122,562</u>
Current Assets			
Stocks	8	119,850	120,650
Debtors	9	116,263	480,552
Cash and cash equivalents		<u>305,904</u>	<u>143,703</u>
		<u>542,017</u>	<u>744,905</u>
Creditors: amounts falling due within one year	10	<u>(305,598)</u>	<u>(236,349)</u>
Net Current Assets		<u>236,419</u>	<u>508,556</u>
Total Assets less Current Liabilities		<u>680,221</u>	<u>631,118</u>
Creditors: amounts falling due after more than one year	11	<u>(298,158)</u>	<u>(66,157)</u>
Net Assets		<u><u>382,063</u></u>	<u><u>564,961</u></u>
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings		<u>381,963</u>	<u>564,861</u>
Equity attributable to owners of the company		<u><u>382,063</u></u>	<u><u>564,961</u></u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Premier Morts Medical Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial period and of its profit or loss for such a financial period and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 19 February 2026 and signed on its behalf by:

Seyed Mohammad Mortazavi
Director

Leila Afsar
Director

Premier Morts Medical Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period ended 31 December 2025

1. General Information

Premier Morts Medical Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 671782. The registered office of the company is 36 The Sycamore, Parkview, Stepside, Dublin 18. The Business address of the company is Long Mile Pharmacy, 1 Long Mile Road, Dublin 12. Dispensing Chemist The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial period ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial period, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Turnover comprises the fair value of consideration received and receivable exclusive of value added tax and after discounts and rebates.

Where the consideration receivable in cash or cash equivalents is deferred, and the arrangement constitutes a financing transaction, the fair value of the consideration is measured as the present value of all future receipts using the imputed rate of interest.

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, usually on dispatch of the goods, the amount of turnover can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Turnover from the provision of services is recognised in the accounting period in which the services are rendered and the outcome of the contract can be estimated reliably. The company uses the percentage of completion method based on the actual service performed as a percentage of the total services to be provided.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 20% Straight line
Motor vehicles	- 20% Reducing Balance

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Investment properties

Investment property is property held either to earn rental income, or for capital appreciation (including future re-development) or for both, but not for sale in the ordinary course of business.

Investment property is initially measured at cost, which includes the purchase cost and any directly

Premier Morts Medical Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period ended 31 December 2025

attributable expenditure. Investment property is subsequently valued at its fair value at each reporting date, by professional external valuers. The difference between the fair value of an investment property at the reporting date and its carrying value prior to the valuation is recognised in the Profit and Loss Account as a fair value gain or loss. Any gain or loss on disposal of an investment property (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in the Profit and Loss Account.

Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.

Leasing

Rentals payable under operating leases are dealt with in the Profit and Loss Account as incurred over the period of the rental agreement.

Stocks

Stocks are valued at the lower of cost and estimated selling price less costs to complete and sell. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Estimated selling price less costs to complete and sell comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial period and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Premier Morts Medical Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period ended 31 December 2025

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Period of financial statements

The financial statements are for the 5 month period ended 31 December 2025.

4. Operating profit

Operating profit is stated after charging:

	Dec 25 €	Jul 25 €
Depreciation of tangible assets	15,753	42,115
Loss on disposal of tangible assets	3,000	11,128
Loss on foreign currencies	2	4
	<u>18,755</u>	<u>53,247</u>

5. Interest payable and similar expenses

	Dec 25 €	Jul 25 €
Interest	<u>5,655</u>	<u>16,093</u>

6. Employees

The average monthly number of employees during the financial period was as follows:

	Dec 25 Number	Jul 25 Number
Directors	2	2
Employees	7	7
	<u>9</u>	<u>9</u>

7. Tangible assets

	Investment properties €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost				
At 1 August 2025	-	105,576	105,000	210,576
Additions	323,891	13,102	-	336,993
At 31 December 2025	<u>323,891</u>	<u>118,678</u>	<u>105,000</u>	<u>547,569</u>
Depreciation				
At 1 August 2025	-	67,014	21,000	88,014
Charge for the financial period	-	8,753	7,000	15,753
At 31 December 2025	<u>-</u>	<u>75,767</u>	<u>28,000</u>	<u>103,767</u>
Net book value				
At 31 December 2025	<u>323,891</u>	<u>42,911</u>	<u>77,000</u>	<u>443,802</u>
At 31 July 2025	<u>-</u>	<u>38,562</u>	<u>84,000</u>	<u>122,562</u>

8. Stocks

	Dec 25 €	Jul 25 €
Finished goods and goods for resale	<u>119,850</u>	<u>120,650</u>

The replacement cost of stock did not differ significantly from the figures shown.

Premier Morts Medical Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period ended 31 December 2025

9. Debtors	Dec 25	Jul 25
	€	€
Trade debtors	77,036	67,942
Amounts owed by group undertakings	-	329,956
Other debtors	2,250	2,250
Directors' current accounts	3,409	21,540
Taxation	28,863	51,534
Prepayments	4,705	7,330
	<u>116,263</u>	<u>480,552</u>
	<u>116,263</u>	<u>480,552</u>
10. Creditors	Dec 25	Jul 25
Amounts falling due within one year	€	€
Amounts owed to credit institutions	75,667	53,607
Net obligations under finance leases and hire purchase contracts	16,743	15,980
Trade creditors	85,077	107,007
Amounts owed to group undertakings	53,333	-
Taxation	69,140	54,883
Accruals	5,638	4,872
	<u>305,598</u>	<u>236,349</u>
	<u>305,598</u>	<u>236,349</u>
11. Creditors	Dec 25	Jul 25
Amounts falling due after more than one year	€	€
Bank loan	239,206	-
Finance leases and hire purchase contracts	58,952	66,157
	<u>298,158</u>	<u>66,157</u>
	<u>298,158</u>	<u>66,157</u>
Loans		
Repayable in one year or less, or on demand	75,667	53,607
Repayable between one and two years	50,816	-
Repayable between two and five years	188,390	-
	<u>314,873</u>	<u>53,607</u>
	<u>314,873</u>	<u>53,607</u>
Net obligations under finance leases and hire purchase contracts		
Repayable within one year	16,743	15,980
Repayable between one and five years	58,952	66,157
	<u>75,695</u>	<u>82,137</u>
	<u>75,695</u>	<u>82,137</u>
12. Income Statement	Dec 25	Jul 25
	€	€
At 1 August 2025	564,861	465,196
Profit for the financial period	63,769	99,665
Payment of dividends	(246,667)	-
	<u>381,963</u>	<u>564,861</u>
At 31 December 2025	<u>381,963</u>	<u>564,861</u>

Premier Morts Medical Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period ended 31 December 2025

13. Financial commitments

All operating lease commitments are now finished.

14. Capital commitments

The company had no material capital commitments at the financial period-ended 31 December 2025.

15. Directors' remuneration

	Dec 25	Jul 25
	€	€
Remuneration	<u>162,557</u>	<u>212,504</u>

16. Related party transactions

The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.

17. Parent company

The company regards Shiraz Investments Limited as its parent company.

18. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial period-end.

19. Ultimate Controlling Party

The ultimate controlling party of the company is Seyed Mohammad Mortazavi.

20. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 19 February 2026.